Under construction – not a live service
Sign in
Taking peopleNo phase

Effects of a Isokinetic Exercise in Women With Fibromyalgia

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
European University Miguel de Cervantes
Trial code
NCT07483216
Record updated
16 April 2026
Original description
Fibromyalgia is a chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and functional impairment, which significantly affects quality of life. Physical exercise is considered one of the most effective non-pharmacological interventions for the management of this condition; however, uncertainty remains regarding the most appropriate type, intensity, and frequency of exercise for different patient profiles. The aim of this study is to analyze the effects of a microdoses isokinetic exercise program on physical condition, perceived pain, inflammatory profile and quality of life in women diagnosed with fibromyalgia.Read full original descriptionShow less

Effects of a Microdoses Isokinetic Exercise Protocol in Women With Fibromyalgia

Fibromyalgia is a chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and functional impairment, which significantly affects quality of life. Physical exercise is considered one of the most effective non-pharmacological interventions for the management of this condition; however, uncertainty remains regarding the most appropriate type, intensity, and frequency of exercise for different patient profiles. The aim of this study is to analyze the effects of a microdoses isokinetic exercise program on physical condition, perceived pain, inflammatory profile and quality of life in women diagnosed with fibromyalgia.

Inclusion: Women aged ≥ 18 years diagnosed with fibromyalgia according to current clinical criteria; Clinical and pharmacological stability during the weeks prior to participation in the study; Ability to perform supervised exercise and to complete the assessments; Written informed consent.

Exclusion: Any condition that, in clinical judgement, prevents them from following the protocol safely; Cardiovascular, neurologic, musculoskeletal or systemic pathology that contraindicate the performance of exercise; Significant change in pharmacological treatment during the period immediately preceding the study.

ClinicalTrials.gov NCT07483216